Drug delivery system HAPE-PLL-PEG (at) EDV capable of simultaneously capturing cfDNA and ROS and application of drug delivery system HAPE-PLL-PEG (at) EDV

Through the drug delivery system co-assembled by the amphiphilic polymer HAPE-PLL-PEG and EDV, the shortcomings of cfDNA capture and antioxidants in the prior art in the treatment of cerebral hemorrhage and secondary brain injury are solved, and the brain hemorrhage is achieved The precise regulation of neuroinflammatory and oxidative stress significantly improves the therapeutic effect and safety.

CN118909245APending Publication Date: 2024-11-08THE FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410838792.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing cfDNA capture materials and antioxidants have defects in the treatment of cerebral hemorrhage and secondary brain injury, which are highly toxic, low bioavailability, and inability to accurately capture cfDNA and oxidative stress, resulting in insufficient efficacy.

Method used

A drug delivery system co-assembled with EDV was developed for amphiphilic polymer HAPE-PLL-PEG and EDV. It forms nano-scale particles through self-assembly to achieve simultaneous capture and delivery of cfDNA and ROS, using "in-situ disassembly-reassembly" "Mode precisely releases EDV at the lesion site, regulating neuroinflammation and oxidative stress.

Benefits of technology

Improve the bioavailability and therapeutic effect of the drug, reduce adverse reactions, and provide new strategies for cerebral hemorrhage and secondary brain injury, significantly inhibit neuroinflammatory and oxidative stress, which is better than traditional drugs in clinical applications. Performance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909245A_ABST
    Figure CN118909245A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of drug delivery, and particularly relates to a drug delivery system HAPE-PLL-PEG (at) EDV capable of simultaneously capturing cfDNA and ROS and application of the drug delivery system HAPE-PLL-PEG (at) EDV. By simultaneously capturing and regulating cell free DNA (cfDNA) and reactive oxygen species (ROS) in pathological processes such as neuroinflammation and oxidative stress, the system provides a new strategy for treating cerebral hemorrhage (ICH) and secondary brain injury (SBI) related diseases. By means of the system, efficient packaging and delivery of the medicine are achieved, and the bioavailability and the treatment effect of the medicine are improved. The amphiphilic polymer HAPE-PLL-PEG provided by the invention has good biocompatibility and biodegradability, the adverse reaction in the treatment process is reduced, and a safety guarantee is provided for clinical application. The drug delivery system HAPE-PLL-PEG (at) EDV provided by the invention has a wide application prospect in the aspect of preventing, inhibiting or treating neuroinflammation and / or oxidative stress related diseases, and a new choice is provided for the treatment of the related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of drug delivery, and more specifically relates to a drug delivery system HAPE-PLL-PEG@EDV capable of simultaneously capturing cfDNA and ROS and applications thereof. Background Art

[0002] The Global Burden of Disease report points out that intracerebral hemorrhage (ICH) is a common type of stroke with high lethality, with a mortality rate of up to 50% within one year. In addition, survivors also suffer from lifelong neurological impairment, such as cognitive and behavioral dysfunction, which imposes a serious economic and health burden on families and society. ICH can cause primary brain injury and secondary brain injury (SBI). SBI occurs within the first few days to weeks after the primary injury, involving a variety of pathological changes to further aggravate brain damage, among which neuroinflammation and oxidative stress, as the main driving factors, become the main causes of SBI.

[0003] In the past few decades, many neuroprotective drugs, such as antioxidants, anti-inflammatory agents, or cell death inhibitors, have been developed for the treatment of ICH, but so far there has been no successful clinical transformation due to insufficient efficacy. In recent years, cfDNA degradation / capture materials have been widely used in preclinical studies for the treatment of cfDNA-related diseases. For example, deoxyribonuclease I (DNase I) reduces cfDNA levels by directly cleaving DNA chains, but its nonspecificity leads to serious side effects and greatly limits clinical application. In addition, with the rapid development of biomaterials, cationic polymers / nanomaterials have been found to have therapeutic effects on certain cfDNA-related diseases by capturing negatively charged cfDNA to block its recognition / activation of pattern recognition receptors. These representative materials include polylysine (PLL), polyethyleneimine (PEI), polyamidoamine (PAMAM), etc. However, traditional cationic materials still have some basic defects that lead to the loss of clinical application, namely, severe toxicity and immunogenicity caused by high positive charge; lack of precise methods to capture cfDNA in situ at the lesion; low bioavailability due to the strict restrictions of the blood-brain barrier. Therefore, there is an urgent need to develop new cfDNA capture materials to overcome the above-mentioned shortcomings and open up new opportunities for the precise regulation of neuroinflammation.

[0004] In addition to neuroinflammation, oxidative stress, another key pathological factor of post-stroke brain injury (SBI), is mainly treated with the antioxidant neuroprotective drug edaravone (EDV) to reduce the levels of hydroxyl radicals and superoxide radicals. Although EDV has strong therapeutic potential, its poor water solubility, short half-life and low bioavailability greatly limit its therapeutic effect. Therefore, it is necessary to develop an advanced delivery platform to release EDV at the lesion site to achieve precise regulation of oxidative stress. Summary of the invention

[0005] In view of the above technical problems, the present invention provides a drug delivery system HAPE-PLL-PEG@EDV and its application that can simultaneously capture cfDNA and ROS, so as to solve the technical problems in the above background technology.

[0006] To achieve the above objectives, in a first aspect, the present invention provides an amphiphilic polymer HAPE-PLL-PEG, the chemical structure of which is shown below:

[0007] Here, R is a cationic polymer containing an amino group.

[0008] Preferably, the cationic polymer containing amino groups is polyethylene glycol-poly-L-lysine.

[0009] More preferably, the nanoparticles formed by self-assembly in aqueous solution have a Z average particle size of about 20 nm to 500 nm and a zeta potential of about -4 mV to 0 mV.

[0010] In some preferred embodiments, the grafting rate of HAPE in the amphiphilic polymer HAPE-PLL-PEG is greater than 30%, preferably, the grafting rate of HAPE is 30% to 90%.

[0011] In a second aspect, the present invention provides a drug delivery system HAPE-PLL-PEG@EDV that can simultaneously capture cfDNA and ROS, which is obtained by co-assembling the amphiphilic polymer HAPE-PLL-PEG of the first aspect of the present invention and EDV.

[0012] Preferably, the Z average particle size of the drug delivery system HAPE-PLL-PEG@EDV is about 60nm to 80nm, and the zeta potential is -15mV to -12mV. More preferably, the Z average particle size of the drug delivery system HAPE-PLL-PEG@EDV is about 70nm, and the zeta potential is -15mV.

[0013] In a third aspect, the present invention provides a method for preparing an amphiphilic polymer HAPE-PLL-PEG, comprising the following steps:

[0014] Activation: dissolving HAPE in an organic solvent, adding a carbonyldiimidazole compound for activation reaction, washing, drying, and concentrating to obtain activated HAPE;

[0015] The polymer synthesis step is as follows: PLL-PEG is dissolved in a polar solvent, an organic base is added and mixed uniformly for pretreatment, the activated HAPE and the catalyst are added, and the mixture is stirred and reacted at a certain temperature for a certain time under a N2 atmosphere, dialyzed, and freeze-dried to obtain an amphiphilic polymer HAPE-PLL-PEG, wherein the amount ratio of the HAPE to the PLL-PEG is 0.5 to 10:1 by mass.

[0016] The organic solvent includes but is not limited to organic solvents such as dichloromethane, chloroform and tetrahydrofuran that can dissolve HAPE. The polar solvent includes but is not limited to dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), N-methylpyrrolidone (NMP) and acetone. The organic base includes but is not limited to triethylamine, diisopropylethylamine (DIPEA), pyridine and piperidine.

[0017] In some preferred embodiments, the carbonyldiimidazole compound is CDI, and the usage ratio of HAPE to CDI is 1:1-1.5 by weight.

[0018] In some preferred embodiments, the catalyst is 4-dimethylaminopyridine.

[0019] In a fourth aspect, the present invention provides a method for preparing a drug delivery system HAPE-PLL-PEG@EDV, comprising the step of co-assembling the amphiphilic polymer HAPE-PLL-PEG described in the first aspect of the present invention or the amphiphilic polymer HAPE-PLL-PEG prepared by the preparation method described in the third aspect of the present invention with EDV by dialysis.

[0020] Preferably, the usage ratio of the amphiphilic polymer HAPE-PLL-PEG to EDV is 10:3 by mass.

[0021] In a fifth aspect, the present invention provides use of the drug delivery system HAPE-PLL-PEG@EDV as described in the second aspect of the present invention in the preparation of a drug for preventing, inhibiting or treating neuroinflammation and / or oxidative stress.

[0022] Different from the prior art, the drug delivery system HAPE-PLL-PEG@EDV provided by the above technical solution can simultaneously capture cell-free DNA (cfDNA) and reactive oxygen species (ROS) in pathological processes such as neuroinflammation and oxidative stress. By simultaneously regulating these two factors, the system provides a new strategy for the treatment of intracerebral hemorrhage (ICH) and secondary brain injury (SBI) related diseases. By co-assembling the amphiphilic polymer HAPE-PLL-PEG with EDV, the system achieves efficient encapsulation and delivery of drugs, improves the bioavailability and therapeutic effect of the drugs. The amphiphilic polymer HAPE-PLL-PEG provided by the present invention has good biocompatibility and biodegradability, reduces adverse reactions during treatment, and provides safety guarantees for clinical applications.

[0023] In summary, the drug delivery system HAPE-PLL-PEG@EDV has broad application prospects in preventing, inhibiting or treating neuroinflammation and / or oxidative stress-related diseases, providing a new option for the treatment of related diseases. At the same time, the results of this invention provide a new and precise strategy for the rational design of the next generation of cfDNA / ROS capture materials, and further explore and reveal its intervention mechanism, laying a good technical foundation for expanding its application in other complex diseases.

[0024] The above-mentioned records related to the invention content are only an overview of the technical solution of the present application. In order to enable ordinary technicians in the field to more clearly understand the technical solution of the present application, and then implement it according to the text of the specification and the contents recorded in the drawings, and to make the above-mentioned purpose and other purposes, features and advantages of the present application easier to understand, the following is an explanation in combination with the specific implementation mode and drawings of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] The drawings are only used to illustrate the principles, implementation methods, applications, characteristics and effects of the specific embodiments of the present application and other related contents, and shall not be considered as limitations of the present application.

[0026] In the drawings of the specification:

[0027] Figure 1 This is the result of the correlation between cfDNA level and the severity of ICH;

[0028] Figure 2 This is a schematic diagram of the "in situ disassembly-reassembly" model of HAPE-PLL-PEG and EDV according to the present invention;

[0029] Figure 3 To confirm the NMR results of the chemical structure of HAPE-PLL-PEG;

[0030] Figure 4The load capacity result of the EDV of Example 2 of the present invention;

[0031] Figure 5 The Z-average particle size (A), zeta potential (B) and transmission electron microscopy (TEM) morphology (C) results of HAPE-PLL-PEG@EDV of Example 2 of the present invention measured under different conditions;

[0032] Figure 6 The release characteristics (A), antioxidant properties (B) and DNA binding affinity (C) results of the HAPE-PLL-PEG@EDV drug of the present invention;

[0033] Figure 7 The HAPE-PLL-PEG@EDV of the present invention inhibits neuronal inflammation driven by cfDNA, wherein A is the correlation result between cfDNA level and severity of cerebral hemorrhage; B and C are the correlation results between serum proinflammatory cytokines TNF-α and IL-6 levels and severity of cerebral hemorrhage, respectively; D and E are the distribution diagrams of TLR9 activation degree and immunofluorescence staining results of cfDNA pattern recognition receptor, respectively; FH are the results of increased mRNA levels of RT-PCR tests of transcription factors Rela, Tnf and Il6, respectively;

[0034] Figure 8 The results of the in vivo inhibitory effect of HAPE-PLL-PEG@EDV of the present invention on neuroinflammation and oxidative stress, wherein A and B are respectively the immunofluorescence staining results of the significant infiltration and activation of microglia and astrocytes, which aggravate neuronal inflammation and cause a large increase in Iba-1 and GFAP positive cells; C and D are respectively the ELISA results of the increased levels of proinflammatory cytokines TNF-α and IL-6 in the perihematoma area; E and F are respectively the immunofluorescence staining results and relative mean fluorescence intensity of 8-OHG antibody in brain tissue sections;

[0035] Fig. 9 The neuroanatomical structure results of the perihematoma area after ICH, where A and B are the results of H&E and Nissl staining; C is the number of Nissl-positive cells in each field of view, D is the ratio of TUNEL-positive cells to total DAPI-positive cells, E is the ratio of NeuN-positive cells to total DAPI-positive cells, and F is the expression levels of anti-apoptotic proteins and pro-apoptotic proteins.

[0036] Fig.10 The in vivo biosafety evaluation results of HAPE-PLL-PEG and HAPE-PLL-PEG@EDV of the present invention are shown in Figure 1, wherein AN represents common blood routine and biochemical indicators, and O represents the H&E staining results of major organs. DETAILED DESCRIPTION

[0037] In order to explain in detail the possible application scenarios, technical principles, specific schemes that can be implemented, and the purposes and effects that can be achieved, the following is a detailed description of the specific embodiments listed in conjunction with the accompanying drawings. The embodiments described herein are only used to more clearly illustrate the technical solutions of the present application, and are therefore only used as examples, and cannot be used to limit the scope of protection of the present application.

[0038] Reference to "embodiment" herein means that the specific features, structures or characteristics described in conjunction with the embodiment may be included in at least one embodiment of the present application. The term "embodiment" appearing in various places in the specification does not necessarily refer to the same embodiment, nor does it particularly limit its independence or association with other embodiments. In principle, in the present application, as long as there is no technical contradiction or conflict, the various technical features mentioned in the embodiments can be combined in any way to form a corresponding implementable technical solution.

[0039] Unless otherwise defined, the technical terms used in this document have the same meanings as those generally understood by those skilled in the art to which this application belongs; the use of relevant terms in this document is only for describing specific embodiments and is not intended to limit this application.

[0040] In the description of this application, the term "and / or" is an expression used to describe the logical relationship between objects, indicating that three relationships may exist, for example, A and / or B, which means: A exists, B exists, and A and B exist at the same time. In addition, the character " / " in this article generally indicates that the objects before and after are in an "or" logical relationship.

[0041] In the present application, terms such as “first” and “second” are merely used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship of quantity, priority or sequence between these entities or operations.

[0042] Without further limitations, in this application, the words "include", "comprises", "has" or other similar expressions used in the sentences are intended to cover non-exclusive inclusion. These expressions do not exclude the presence of additional elements in the process, method or product including the elements, so that the process, method or product including a series of elements may include not only those limited elements, but also other elements not explicitly listed, or also include elements inherent to such process, method or product.

[0043] Similar to the understanding in the Examination Guidelines, in this application, expressions such as "greater than", "less than", "exceed" and the like are understood to exclude the number itself; expressions such as "above", "below", "within" and the like are understood to include the number itself. In addition, in the description of the embodiments of this application, "multiple" means more than two (including two), and similar expressions related to "multiple" are also understood in this way, such as "multiple groups", "multiple times", etc., unless otherwise clearly and specifically limited.

[0044] In the description of the embodiments of the present application, space-related expressions used, such as "center", "longitudinal", "lateral", "length", "width", "thickness", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "vertical", "top", "bottom", "inside", "outside", "clockwise", "counterclockwise", "axial", "radial", "circumferential", etc., indicate the orientation or position relationship based on the orientation or position relationship shown in the specific embodiments or drawings, and are only for the convenience of describing the specific embodiments of the present application or facilitating the reader's understanding, and do not indicate or imply that the referred device or component must have a specific position, a specific orientation, or be constructed or operated in a specific orientation, and therefore cannot be understood as a limitation on the embodiments of the present application.

[0045] Unless otherwise expressly specified or limited, in the description of the embodiments of the present application, the terms such as "install", "connect", "connect", "fix", "set", etc. used should be understood in a broad sense. For example, the "connection" can be a fixed connection, a detachable connection, or an integrated setting; it can be a mechanical connection, an electrical connection, or a communication connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium; it can be the internal connection of two elements or the interaction relationship between two elements. For technicians in the technical field to which the present application belongs, the specific meanings of the above terms in the embodiments of the present application can be understood according to the specific circumstances.

[0046] Several studies have reported a new mechanism of inflammation-driven development, in which cell-free DNA (cfDNA) from dead or dying cells of injured tissues is highlighted as damage-associated molecular patterns (DAMPs) and is recognized by pattern recognition receptors of immune cells, triggering uncontrolled local or systemic inflammation. This plays a crucial role in a variety of serious diseases associated with inflammation. In the process of obtaining the present invention, we found that the cfDNA level of clinical patients was positively correlated with the severity of ICH (see Figure 1). Therefore, it is reasonable to assume that cfDNA may be a new and feasible therapeutic target to prevent neuroinflammation in SBI. In recent years, cfDNA degradation / capture materials have been widely used in preclinical studies for the treatment of cfDNA-related diseases. For example, deoxyribonuclease I (DNase I) reduces cfDNA levels by directly cleaving DNA chains, but its nonspecificity leads to serious side effects and greatly limits clinical applications. In addition, with the rapid development of biomaterials, cationic polymers / nanomaterials have been found to have therapeutic effects on certain cfDNA-related diseases by capturing negatively charged cfDNA to block its recognition / activation of pattern recognition receptors. These representative materials include polylysine (PLL), polyethyleneimine (PEI), polyamidoamine (PAMAM), etc. However, traditional cationic materials still have some basic defects that lead to the loss of clinical application, namely, severe toxicity and immunogenicity caused by high positive charge; lack of precise methods to capture cfDNA in situ at the lesion; and low bioavailability due to the strict restrictions of the blood-brain barrier. Therefore, there is an urgent need to develop a new cfDNA capture material to overcome the above defects and open up new opportunities for the precise regulation of neuroinflammation. In addition, drugs with multiple targets, especially those that can simultaneously reduce neuroinflammation and oxidative stress, can achieve effective clinical benefits and are a promising treatment strategy. Therefore, it is crucial to develop new drugs that can simultaneously reduce neuroinflammation and oxidative stress and study related targets to rationally control neuroinflammation and oxidative stress and effectively prevent SBI.

[0047] The “disassembly-drug release” model has been widely used to spatially control drug release to improve efficacy. Based on this, the present invention further improves and proposes an “in situ disassembly-reassembly” model (see Figure 2 ) to simultaneously address the dual challenges of neuroinflammation and oxidative stress in SBI after intracerebral hemorrhage (ICH). This model is activated by the pathogenesis of SBI after stroke to accurately capture cfDNA / ROS, thereby effectively preventing SBI after intracerebral hemorrhage (ICH). The present invention uses ROS-activating molecules from 4-hydroxyphenylboronic acid pinacol ester (HAPE) to graft polyethylene glycol-poly-L-lysine (PLL-PEG) to prepare an amphiphilic polymer HAPE-PLL-PEG, and then the amphiphilic polymer HAPE-PLL-PEG and edaravone (EDV) are co-assembled to construct a functional delivery system loaded with EDV (HAPE-PLL-PEG@EDV). During the delivery process, the system has a negative charge, nanoscale size and a PEG shielding layer, thereby exhibiting low toxicity, high formulation stability and locked capture of cfDNA to minimize side effects.

[0048] The animal experiments of the present invention were conducted in accordance with the Animal Care Guidelines of Fujian Medical University (IACUC FJMU2024-Y-0857), and also complied with the “Guide for the Care and Use of Laboratory Animals” of the National Institutes of Health of the United States.

[0049] In vivo biosafety assessment of the present invention: The biosafety at the blood and organ levels was assessed in vivo. On the 7th day, blood samples were extracted from the inner canthus for routine blood tests and blood biochemical tests to reveal physiological indicators, liver and kidney function, thereby assessing the biosafety at the blood level. In addition, major organs (including heart, liver, spleen, lungs and kidneys) were collected on the 7th day for HE staining to detect damage for the assessment of biosafety at the organ level.

[0050] Statistical analysis of the present invention: The statistical results were analyzed by unpaired two-tailed Student's t test to compare unpaired two groups, and by one-way analysis of variance (ANOVA) test to compare multiple groups of data. Data are expressed in the form of mean ± standard error (SEM), where *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 indicate statistical significance.

[0051] In the specific embodiments of the present invention, the chemicals and materials used are described as follows:

[0052] 4-Hydroxyphenylboronic acid pinacol ester (HAPE), edaravone (EDV), anhydrous DMSO, dichloromethane, N,N'-carbonyldiimidazole (CDI), sodium chloride, sodium sulfate, 4-dimethylaminopyridine, and triethylamine were purchased from MacLean Biochemical Technology Co., Ltd. (Shanghai, China). Polyethylene glycol-poly-L-lysine PLL-PEG (the average molecular weights of PLL and PEG were 5k and 2kDa, respectively) was provided by Meiluo Technology Co., Ltd. (Shenzhen, China). TUNEL apoptosis detection kit and 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) were purchased from Meilun Biotechnology Co., Ltd. (Dalian, China). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), cell counting kit-8 (CCK-8), and Lysotracker Green were purchased from Invitrogen Biotechnology Co., Ltd. (USA). IL-6 ELISA kit and TNF-α ELISA kit were purchased from Solebao Technology Co., Ltd. (Beijing, China). The primary antibodies required for immunofluorescence and immunohistochemistry experiments, including TLR9 (ab134368), GFAP (ab7260), Iba-1 (ab178847), TNF-α (ab183218), IL-6 (ab290735), 8-OHG (ab48508) and NeuN (ab177487), were purchased from commercial sources. Other chemicals were of analytical grade and no further purification was required.

[0053] Example 1 Synthesis of HAPE-PLL-PEG

[0054] 4-Hydroxyphenylboronic acid pinacol ester (1.0 g) was dissolved in dichloromethane (10 mL), and then N,N'-carbonyldiimidazole (CDI, 1.4 g) was added. After stirring for 30 minutes, dichloromethane (10 mL) was added to the solution again, and then washed three times with deionized water. The organic phase was separated, washed three times with saturated sodium chloride solution, dried with sodium sulfate, and then concentrated and dried under vacuum to obtain 4-hydroxyphenylboronic acid pinacol ester activated with CDI.

[0055] PLL-PEG (0.5 g) was dissolved in anhydrous DMSO (50 mL), and then triethylamine (0.78 mL) was added to the solution and stirred at room temperature for 1 hour. Subsequently, CDI-activated 4-hydroxyphenylboronic acid pinacol ester (1.1 g) and 4-dimethylaminopyridine (0.61 g) were added and stirred at 35°C for 24 hours under N2 atmosphere. Finally, the solution was dialyzed and lyophilized to obtain HAPE-PLL-PEG polymer. The chemical structure of HAPE-PLL-PEG was confirmed by 1H NMR (see Figure 3 ), as shown in Formula 1.

[0056]

[0057] Wherein, R is a cationic polymer containing an amino group, preferably polyethylene glycol-poly-L-lysine PLL-PEG. Therefore, HAPE-PLL-PEG is an amphiphilic polymer.

[0058] Using Zeta sizerNano ZS to monitor, the Z average particle size was about 59 nm and the zeta potential was about -12 mV.

[0059] Example 2 Preparation of HAPE-PLL-PEG@EDV

[0060] In this example, HAPE-PLL-PEG@EDV was prepared by dialysis. HAPE-PLL-PEG (100 mg) and EDV (30 mg) prepared in Example 1 were dissolved in DMSO (8 mL) and then slowly added dropwise to deionized water (16 mL) under vigorous stirring. The solution was dialyzed in deionized water (MWCO = 3500 Da) for 24 hours to remove DMSO and small molecule impurities. Then, the solution was filtered using a 0.45 μm hydrophilic filter to remove large aggregates. Finally, it was lyophilized to obtain HAPE-PLL-PEG@EDV.

[0061] During the preparation process, the dialysis medium was collected and then the loading capacity of EDV, i.e., the loading capacity (LC) and loading efficiency (LE), was measured by the difference method using a UV-visible spectrophotometer. The loading capacity (LC) and loading efficiency (LE) were calculated using the following formulas. Figure 4 .

[0062] Loading amount (%) = (loaded weight of EDV / total weight of HAPE-PLL-PEG@EDV)*100%,

[0063] Loading efficiency (%) = (EDV loading weight / EDV feed weight)*100%.

[0064] Example 3 ROS-activated in situ dissociation-reconstitution

[0065] The HAPE-PLL-PEG@EDV prepared in Example 2 was dispersed in PBS (10 mM, pH = 7.4) containing 1.0 mM H2O2 and then placed in a constant temperature shaker at about 37°C and 100 rpm. At different time points, 3 mL of the solution was taken out and the same volume of buffer was added. The solution was tested for Z-average diameter (Z-average particle size) and zeta potential using Zeta sizerNano ZS, and the morphology was observed by transmission electron microscopy (TEM), please refer to Figure 5 .

[0066] Pathological factors directly trigger the property transformation of HAPE-PLL-PEG from amphiphilic to hydrophilic, thereby inducing the in situ disintegration of the HAPE-PLL-PEG@EDV system. Subsequently, the regenerated cationic polymer PLL-PEG binds to the negatively charged pathological cfDNA through electrostatic interactions to reconstitute the PLL-PEG@cfDNA nanocomplex. To characterize this continuous process, Zeta sizer Nano ZS and TEM observations were performed. After adding 1mM H2O2, the Z-average particle size of HAPE-PLL-PEG@EDV was greatly reduced from about 70nm to about 33nm, and the zeta potential was reversed from about -15mV to about +31mV( Figure 5 , AB). These results indicate that the disappearance of the hydrophobic driving force leads to the disintegration of HAPE-PLL-PEG@EDV from nanoparticles to polymers and the regeneration of polycationic PLL-PEG. Subsequently, the introduction of calf thymus DNA (a typical double-stranded DNA) increased the Z-average particle size to about 138 nm and decreased the zeta potential to about +2.8 mV ( Figure 5 , AB). This indicates that DNA is loaded by PLL-PEG through electrostatic adsorption to form nanosized complexes, a process known as the recombination process. TEM results also support this disassembly-recombination process by observing that the continuous treatment of H2O2 and calf thymus DNA causes the morphology of HAPE-PLL-PEG@EDV to change from initially small nanospheres to eventually relatively large nanospheres ( Figure 5 , C).

[0067] As key elements, the drug's release properties, antioxidant properties, and cfDNA binding affinity were further investigated.

[0068] First, the release characteristics of EDV were examined by ultraviolet-visible spectroscopy (UV-Vis). The results showed that EDV was released in a controlled manner under different H2O2 levels, with a cumulative release rate of about 76% within 12 h under 1 mM H2O2, while it was only about 4% without H2O2 incubation ( Figure 6 , A). This supports that HAPE-PLL-PEG@EDV remains stable during delivery and then releases EDV precisely at the lesion site to improve efficacy and safety.

[0069] Next, a 2,2-diphenyl-1-pyridohydrazine (DPPH) experiment was performed to evaluate the antioxidant properties of HAPE-PLL-PEG@EDV. An ethanol solution of DPPH was mixed with different concentrations of HAPE-PLL-PEG@EDV, and then the mixed solution was placed in an oscillating incubator with a constant temperature and a shaking rate of 100 rpm, and oscillated at about 37°C for 30 minutes. Finally, the absorbance value at 515nm was measured by UV-visible spectrometer to reflect the antioxidant potential, in which pure DPPH solution was used as a control. The results showed that HAPE-PLL-PEG was able to inhibit the generation of DPPH free radicals in a dose-dependent manner, and HAPE-PLL-PEG@EDV further enhanced this inhibitory effect, with a scavenging efficiency of more than 90% (at 50 μg / mL). Figure 6 , B). This result indicates that HAPE-PLL-PEG@EDV has ROS scavenging properties, which can be attributed to two aspects: 1) the cleavage of the boronate ester bond and the generated HBA molecules deplete ROS; 2) the released EDV exerts antioxidant activity.

[0070] Furthermore, the cfDNA binding ability of HAPE-PLL-PEG@EDV was evaluated. The cfDNA binding ability of HAPE-PLL-PEG@EDV was evaluated by the Quant-iT PicoGreen double-stranded DNA assay. Calf thymus DNA and PicoGreen reagent were mixed in Tris-EDTA buffer and incubated in the dark for 10 minutes. Then, HAPE-PLL-PEG@EDV, which had been previously incubated in the presence / absence of H2O2 for 1 hour, was added to the above calf thymus DNA solution and incubated in the dark for another 30 minutes. Next, the fluorescence intensity at 520 nm was measured to quantify the DNA bound to HAPE-PLL-PEG@EDV. For the quantification results of DNA bound to HAPE-PLL-PEG@EDV, please refer to Figure 6 , C.

[0071] Afterwards, the DNA binding affinity activated by ROS was studied by competitive binding of Pico Green reagent with dsDNA (short for double-stranded DNA). The study found that HAPE-PLL-PEG@EDV without H2O2 incubation did not bind to dsDNA, but after incubation with 1mM H2O2, it was converted to high affinity (more than 85% at low polymer / DNA ratio = 1), even similar to the cationic polymer PLL-PEG ( Figure 6 , C), which indicates that HAPE-PLL-PEG@EDV has ROS-activated cfDNA capture properties.

[0072] In summary, the ROS-activated in situ dissociation-reconstitution properties of the HAPE-PLL-PEG@EDV delivery system of the present invention were confirmed, and it is expected to play an excellent role in precise cfDNA / ROS capture in subsequent in vitro and in vivo applications.

[0073] Example 4 Controlled Release of EDV in HAPE-PLL-PEG@EDV

[0074] The controlled release of EDV in HAPE-PLL-PEG@EDV prepared in Example 2 was determined by dialysis. 40 mL of PBS (10 mM, pH = 7.4) containing different concentrations of H2O2 (0, 0.1, 0.2, 0.5, 1.0 mM) was added to a 50 mL centrifuge tube, and 0.2 mL of Tween80 was added. Then, the centrifuge tube was placed in a constant temperature shaker at about 37°C and 100 rpm. The prepared 2 mL HAPE-PLL-PEG@EDV solution (1 mg / mL) was loaded into a dialysis bag (MWCO = 1000 Da) and placed in the above-mentioned 50 mL centrifuge tube. At different time points, 3 mL of dialysis medium was taken out and the same volume of buffer was added. The dialysis medium was replaced every 12 hours. The absorption peak of EDV at 242 nm was measured by the UV-Vis method to quantify the release curve. The release curve of EDV is shown in Figure 6 , as shown in A.

[0075] Example 5 Animal model of cerebral hemorrhage and treatment strategy

[0076] In order to simulate clinical cerebral hemorrhage, the present invention uses autologous blood method to establish mouse cerebral hemorrhage model according to previous work. C57BL / 6 mice aged 10-12 weeks were purchased from Shanghai Xilake Experimental Animal Co., Ltd. and randomly divided into six groups (sham operation group, saline group, HAPE-PLL-PEG group, HAPE-PLL-PEG@EDV group, PLL-PEG group and edaravone / right camphor group). The latter five groups of mice were subjected to cerebral hemorrhage model making, and mice were provided with natural circadian rhythm and sufficient food and water before surgery. This animal experiment follows the Animal Protection Guidelines of Fujian Medical University (IACUCFJMU 2024-Y-0857), and also complies with the Guidelines for the Care and Use of Laboratory Animals of the National Institutes of Health of the United States.

[0077] The mice were fully anesthetized using anesthetic gas, and then 1.5% isoflurane was injected to maintain anesthesia. Next, the mice were fixed on a brain stereotaxic instrument, and a bone hole was drilled on the right side of the skull, 2.3 mm lateral to the midline and 0.5 mm in front of the anterior fontanelle. Then, the autologous blood (30 μL) obtained in advance from the angular vein was injected at a rate of 1 μL / min at a depth of 3 mm for 5 minutes. Subsequently, the needle was advanced to a depth of 3.7 mm and remained in place for another 5 minutes to prevent blood from flowing out. The remaining blood (25 μL) was injected at a rate of 1 μL / min. Finally, the suture was sealed with bone wax. As a control, the sham group was injected with saline into the basal ganglia. During the intracerebral hemorrhage surgery, the ambient temperature was maintained at approximately 25°C, and after surgery, the mice were placed on a temperature-controlled blanket and then subjected to a 12-hour light-dark cycle with free access to food and water.

[0078] Example 6 Inhibitory effects on neuroinflammation and oxidative stress in vivo

[0079] After cerebral hemorrhage, uncontrolled neuroinflammatory response and oxidative stress have become important factors that aggravate brain damage. The dual inhibition strategy is regarded as a new hope for effectively preventing brain damage. Therefore, the present invention studies the in vivo inhibitory effect of HAPE-PLL-PEG@EDV on neuroinflammation and oxidative stress.

[0080] To evaluate the in vivo inhibitory effect on neuroinflammation, Quant-iT Pico Green double-stranded DNA kit detection, immunofluorescence staining, immunohistochemical staining, RT-PCR, and ELISA were performed. For the Quant-iT PicoGreen double-stranded DNA kit, blood samples were drawn from the inner canthus on day 7, and the cfDNA level in the serum was examined according to the instructions. For immunofluorescence staining, mice were perfused with saline and 4% paraformaldehyde (PFA) by heart, and then the brains were collected and fixed with 4% PFA. Next, brain tissue sections of approximately 25 μm thickness were prepared, permeabilized with TritonX-100 and serum-treated for primary antibody incubation overnight at 4 °C, including anti-TLR9 antibody, anti-GFAP antibody, anti-Iba-1 antibody, anti-8-OHG antibody, and anti-NeuN antibody. Subsequently, the sections were rinsed three times with PBS and then incubated with Alexa Fluor-conjugated secondary antibodies. DAPI was used as a nuclear stain. For immunohistochemical staining, brain tissue sections were stained with TNF-α and IL-6. For RT-PCR detection, brain tissues from the perihematoma area were collected to support RT-PCR detection to examine the level of Rela. For ELISA detection, brain tissues and blood samples from the perihematoma area were obtained to support IL-6 ELISA kit and TNF-α ELISA kit to detect their IL-6 and TNF-α levels according to their instrument instructions.

[0081] The occurrence of cerebral hemorrhage leads to a significant increase in cfDNA levels in the serum of clinical patients and experimental mice, and the increased levels are positively correlated with the severity of cerebral hemorrhage ( Figure 7 , A). In addition, this was accompanied by an increase in the levels of pro-inflammatory cytokines (TNF-α and IL-6) in serum ( Figure 7 , BC). Therefore, it is speculated that a new neuroinflammatory pattern driven by cfDNA may be triggered. Next, brain tissue from the perihematoma area was isolated for further analysis. Immunofluorescence staining results showed that TLR9, a pattern recognition receptor for cfDNA, was significantly activated and mainly distributed in microglia ( Figure 7 , DE). Then, RT-PCR results showed that the mRNA levels of transcription factors Rela, Tnf, and Il6 were increased, indicating the activation of the NF-κB signaling pathway ( Figure 7 , FH). In addition, significant infiltration and activation of microglia and astrocytes were observed, which aggravated neuronal inflammation as Iba-1 and GFAP-positive cells increased significantly ( Figure 8 , AB). Activated microglia had enlarged cell bodies, while reactive astrocytes showed an increase in processes and hypertrophic changes in cell bodies. In addition, ELISA results confirmed elevated levels of proinflammatory cytokines TNF-α and IL-6 in the perihematoma area ( Figure 8 , CD). All of the above evidence confirms that cfDNA-driven inflammation occurs after ICH. After various treatments, HAPE-PLL-PEG was found to inhibit neuroinflammation by precisely capturing cfDNA in the lesion site, inhibiting the activation of TLR9, NF-κB signaling pathway and glial cells, and downregulating proinflammatory cytokines. More importantly, HAPE-PLL-PEG@EDV has a stronger inhibitory effect on neuroinflammation than HAPE-PLL-PEG, because EDV also exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway. By another comparison, HAPE-PLL-PEG@EDV is even superior to the clinically approved antioxidant / anti-inflammatory drugs edaravone / dexamethasone.

[0082] Then, the present invention further studied the in vivo inhibitory effect against oxidative stress.

[0083] To evaluate the in vivo inhibitory effect on oxidative stress, immunofluorescence staining was performed. The oxidative stress experimental procedure was as follows: approximately 25 μm thick brain tissue sections were prepared for incubation with primary antibodies (including anti-8-OHG antibodies) at 4°C overnight. Then, the sections were washed three times with PBS and incubated with Alexa Fluor-conjugated secondary antibodies. After ICH, significant oxidative damage to neuronal DNA / RNA was detected, as upregulated 8-OHG was mainly localized in neurons ( Figure 8, EF). After HAPE-PLL-PEG@EDV treatment, oxidative damage was greatly alleviated, mainly due to its precise and multiple ROS capture mechanisms: ROS-activated HAPE-PLL-PEG degradation reaction consumed ROS, where ROS is the reactant for cleaving boronate bonds; the generated HBA can scavenge free radicals; and the released EDV exerts pharmacological effects by reducing the levels of hydroxyl radicals and superoxide radicals. These multiple effects make it superior to edaravone / dexamethasone in inhibiting neuronal oxidative damage.

[0084] Example 7 In vivo neuroprotective effects on neural anatomy and neuronal apoptosis

[0085] The above results verify that the functional delivery system HAPE-PLL-PEG@EDV of the present invention can effectively alleviate neuroinflammation and oxidative stress by accurately capturing cfDNA / ROS after ICH. Furthermore, the present invention evaluates its neuroprotective effect on neuroanatomical structure and neuronal apoptosis.

[0086] To evaluate the neuroprotective effects on neuroanatomical structures in vivo, hematoxylin-eosin (H&E) and Nissl staining were performed. The mouse brains were perfused with 10% formalin and then immersed in 4% paraformaldehyde solution at 4°C for 72 h. The brain tissue near the hematoma was embedded in 30% paraffin, cut into 20 μm thick sections, and dewaxed with xylene and graded alcohol. Finally, H&E staining was performed using a hematoxylin and eosin staining kit, and Nissl staining was performed using toluidine blue. The sections were observed and photographed under an optical microscope. In addition, NeuN / TUNEL immunofluorescence staining was applied to characterize neuronal apoptosis. Finally, the brain tissue near the hematoma was used for bulk RNA sequencing to examine the levels of various anti-apoptotic and pro-apoptotic proteins.

[0087] First, we performed H&E and Nissl staining to study the neuroanatomical structure of the perihematoma area. It was observed that ICH caused obvious structural disorder and looseness, with vacuoles. H&E staining showed typical apoptotic features such as nuclear condensation, and Nissl staining showed a significant decrease in Nissl-positive neurons, which confirmed that ICH caused severe secondary damage to functional neurons ( Fig. 9 , AB). HAPE-PLL-PEG@EDV treatment restored the above pathological neuroanatomical structures to normal and significantly increased the integrity and number of neurons ( Fig. 9 , AB).

[0088] In addition, considering that neuroinflammation and oxidative damage may lead to cell death, especially apoptosis, we performed NeuN / TUNEL staining to observe a significant increase in neuronal apoptosis in the perihematoma area after ICH ( Fig. 9, CE). HAPE-PLL-PEG@EDV effectively inhibited neuronal apoptosis, increased neuronal survival and restored neuronal signaling ( Fig. 9 , CE), which is mainly due to the upregulation of anti-apoptotic proteins (Bcl-2, Bcl-6, Bcl-10, Mcl-1) and the downregulation of pro-apoptotic proteins (Bad, Bax, Bak, Bid) ( Fig. 9 , F).

[0089] Therefore, HAPE-PLL-PEG@EDV exerted an excellent neuroprotective effect in restoring normal neural anatomical structure and inhibiting neuronal apoptosis, which was superior to the clinical antioxidant / anti-inflammatory drugs edaravone / dexamethasone and showed a high therapeutic potential.

[0090] Example 8 In vivo biosafety assessment

[0091] In vivo biosafety is an important evaluation criterion for clinical application. The present invention systematically evaluates the in vivo biosafety of HAPE-PLL-PEG@EDV at the blood and organ levels. In vivo biosafety was evaluated at the blood and organ levels, respectively. Blood samples were drawn from the inner canthus on the 7th day for routine blood tests and blood biochemical tests to reveal physiological indicators, liver and kidney function, thereby evaluating blood-level biosafety. In addition, major organs, including heart, liver, spleen, lungs, and kidneys, were collected on the 7th day for hematoxylin-eosin (H&E) staining to detect damage, which is used to evaluate organ-level biosafety. First, after 7 days of administration, routine blood tests and biochemical tests were performed using tail vein blood. The results showed that there were no significant differences in routine hematological indicators and alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine levels between the treatment groups. This indicates that HAPE-PLL-PEG and HAPE-PLL-PEG@EDV have no significant effects on blood cells and liver and kidney function. In addition, mice were sacrificed and major organs (including heart, liver, spleen, lung and kidney) were collected for H&E staining to further explore potential side effects on organ damage. The results showed that at therapeutic doses, the administration of HAPE-PLL-PEG and HAPE-PLL-PEG@EDV did not cause damage and morphological changes in these organs. From the in vivo safety assessment, the functional delivery system of the present invention was confirmed to be biosafe ( Fig.10 ).

[0092] In summary, the present invention uses the reactive oxygen species (ROS) activation molecules of 4-hydroxyphenylboronic acid pinacol ester (HAPE) to chemically modify the PLL-PEG polymer (the molecular weights of PLL and PEG are 5k and 2kDa, respectively) to synthesize the HAPE-PLL-PEG polymer. The 1H NMR test results confirm that the grafting rate of HAPE is about 87.8%. HAPE is a typical hydrophobic structure, which gives HAPE-PLL-PEG amphiphilicity. Therefore, HAPE-PLL-PEG and the hydrophobic drug EDV are co-assembled in aqueous solution to form a bioactive EDV delivery system HAPE-PLL-PEG@EDV, and no precipitation phenomenon is observed in this process. Next, the drug loading and corresponding drug loading efficiency of EDV were detected by ultraviolet-visible spectroscopy (UV-Vis), which were about 11.2% and about 37.2%, respectively. In addition, the properties of the colloid, including particle size and zeta potential, were measured using ZetasizerNano ZS. The results showed that the Z-average particle size of HAPE-PLL-PEG was about 59 nm and the zeta potential was about -12 mV, while the Z-average particle size of HAPE-PLL-PEG@EDV was about 70 nm and the zeta potential was -15 mV. By comparison, the increase in particle size also suggests the successful loading of EDV, while the almost unchanged zeta potential indicates that the loading of EDV has no significant effect on the self-assembly of HAPE-PLL-PEG using PEG as the hydrophilic outer layer.

[0093] Under pathological conditions, the system is activated by overexpressed ROS and spontaneously degrades the HAPE part to regenerate PLL-PEG. At this point, the system first disassembles to release EDV at the lesion site to precisely regulate ROS, and then the regenerated cationic polymer PLL-PEG binds to pathology-related cfDNA through electrostatic interactions, reassembles into cfDNA-encapsulated nanocomplexes, and blocks TLR9 recognition and activation to precisely regulate neuroinflammation. Through this new "in situ disassembly-reassembly" mode, this study simultaneously overcomes the limitations of current cfDNA capture and EDV administration strategies, providing an important therapeutic application for the prevention of SBI after ICH. In addition, it is worth reiterating that this strategy exhibits satisfactory biosafety.

[0094] Finally, it should be noted that although the above embodiments have been described in the specification and drawings of this application, this does not limit the scope of patent protection of this application. All technical solutions generated by replacing or modifying equivalent structures or equivalent processes based on the essential concept of this application using the contents recorded in the specification and drawings of this application, as well as directly or indirectly implementing the technical solutions of the above embodiments in other related technical fields, are included in the scope of patent protection of this application.

Claims

1. An amphiphilic polymer HAPE-PLL-PEG, characterized in that Its chemical structure is shown below: Here, R is a cationic polymer containing an amino group.

2. The amphiphilic polymer HAPE-PLL-PEG according to claim 1, characterized in that The amino group-containing cationic polymer is polyethylene glycol-poly-L-lysine.

3. The amphiphilic polymer HAPE-PLL-PEG according to claim 1, characterized in that The nanoparticles formed by self-assembly in aqueous solution have a Z average particle size of about 20nm to 500nm and a zeta potential of about -40mV to 0mV.

4. The amphiphilic polymer HAPE-PLL-PEG according to claim 1, characterized in that The grafting rate of HAPE is above 30%, and preferably, the grafting rate of HAPE is 30% to 90%.

5. A drug delivery system HAPE-PLL-PEG@EDV that can simultaneously capture cfDNA and ROS, characterized in that: The amphiphilic polymer HAPE-PLL-PEG described in any one of claims 1 to 4 is co-assembled with EDV.

6. The drug delivery system HAPE-PLL-PEG@EDV according to claim 5, characterized in that: The Z average particle size is about 60nm to 80nm, and the zeta potential is -15mV to -12mV.

7. A method for preparing an amphiphilic polymer HAPE-PLL-PEG, characterized in that: The following steps are involved: Activation: dissolving HAPE in an organic solvent, adding a carbonyldiimidazole compound for activation reaction, washing, drying, and concentrating to obtain activated HAPE; The polymer synthesis step is as follows: PLL-PEG is dissolved in a polar solvent, an organic base is added and mixed uniformly for pretreatment, the activated HAPE and the catalyst are added, and the mixture is stirred and reacted at a certain temperature for a certain time under a N2 atmosphere, dialyzed, and freeze-dried to obtain an amphiphilic polymer HAPE-PLL-PEG, wherein the amount ratio of the HAPE to the PLL-PEG is 0.5 to 10:1 by mass.

8. The preparation method according to claim 7, characterized in that: The carbonyldiimidazole compound is CDI, and the usage ratio of HAPE to CDI is 1:1-1.5 by weight.

9. A method for preparing a drug delivery system HAPE-PLL-PEG@EDV, characterized in that: The method comprises the steps of co-assembling the amphiphilic polymer HAPE-PLL-PEG described in any one of claims 1 to 4 or the amphiphilic polymer HAPE-PLL-PEG prepared by the preparation method described in claim 7 or 8 with EDV by dialysis method.

10. Use of the drug delivery system HAPE-PLL-PEG@EDV as claimed in claim 5 in the preparation of a drug for preventing, inhibiting or treating neuroinflammation and / or oxidative stress.